Modulation of cytokine production by some phthalimido-desmuramyl dipeptides and their cytotoxicity

Farmaco

Volumn 59, Issue 5, 2004, Pages 345-352

  Gobec, Stanislav ^a   Sollner Dolenc, Marija ^a   Urleb, Uroš ^a,b   Wraber, Branka ^a   Simčič, Saša ^a   Filipič, Metka ^c  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b Lek dd   (Slovenia)

^c NATIONAL INSTITUTE OF BIOLOGY   (Slovenia)

Author keywords

Cytokines; Cytotoxic activity; Muramyl dipeptide analogues; Phthalimido desmuramyldipeptides; Synthesis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; IONOMYCIN; LK 413; LK 508; LK 511; LK 512; LK 517; MURAMYL DIPEPTIDE DERIVATIVE; N (5 PHTHALIMIDOPENTANOYL) DEXTRO ALANYL DEXTRO ISOGLUTAMINE; PEPTIDOGLYCAN; PHORBOL 13 ACETATE 12 MYRISTATE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL CELL WALL; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IMMUNOMODULATION; PERIPHERAL BLOOD MONONUCLEAR CELL; TH1 CELL; UPREGULATION;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADJUVANTS, IMMUNOLOGIC; CELLS, CULTURED; CYTOKINES; HUMANS; INTERLEUKINS; IONOMYCIN; MODELS, CHEMICAL; MONOCYTES; PROTO-ONCOGENE PROTEINS C-BCL-2; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2142779123     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.farmac.2004.01.003     Document Type: Article

References (53)

1. Ellouz F., Adam A., Cirobaru R., Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem. Biophys. Res. Commun. 59:1974;1317-1325
2. Mašek K. Multiplicity of biological efects of muramyl dipeptide. Methods Find. Exp. Clin. Pharmacol. 8:1986;97-99
3. Bahr G.M., Chedid L. Immunological activities of muramyl peptides. Fed. Proc. 45:1986;2541-2544
4. Riveau G., Mašek K., Parant M., Chedid L. Central pyrogenic activity of muramyl dipeptide. J. Exp. Med. 152:1980;869-877
5. Kikelj D., Pečar S., Kotnik V., Štalc A., Wraber-Herzog B., Simčič S., Ihan A., Klamfer L., Povšič L., Grahek R., Suhadolc E., Hočevar M., Hönig H., Rogi-Kohlenprath R. N-{trans-2-[[2'-(Acetylamino)cyclohexyl]oxy]acetyl}-L-alanyl-D-glutamic acid: a novel immunologically active carbocyclic muramyl dipepeptide analogue. J. Med. Chem. 41:1998;530-539. and references therein
6. Azuma I., Otani T. Potentiation of host defense mechanism against infection by a cytokine inducer, an acyl-MDP derivative, MDP-Lys(L18) (Romurtide) in mice and humans. Med. Res. Rev. 14:1994;401-414
7. Tsubura E., Azuma I., Une T. Muroctasin, a muramyl dipeptide derivative. Arzneim.-Forsch./Drug Res. 38:1988;951-952
8. Adam A., Lederer E. Muramyl peptides: immunomodulators, sleep factors and vitamins. Med. Res. Rev. 4:1984;111-152
9. Baschang G. Muramylpeptides and lipopeptides: studies toward immunostimulants. Tetrahedron. 45:1989;6331-6360
10. Lefrancier P., Lederer E. Muramyl-peptides. Pure Appl. Chem. 59:1987;449-454
11. Hemmi K., Takeno H., Okada S., Nakaguchi O., Kitaura Y., Hashimoto M. Total synthesis of FK-156 isolated from a Streptomyces as an immunostimulating peptide: application of a novel copper chelate amino protection. J. Am. Chem. Soc. 103:1981;7026-7028
12. Migliore-Samour D., Bouchaudon J., Floc'h F., Zerial A., Ninet L., Werner G.H., Jolles P.A. A short lipopeptide, representative of a new family of immunological adjuvans devoid of sugar. Life Sci. 26:1980;883-888
13. Sollner M., Pečar S., Štalc A. The influence of the lipophilicity of the 7-oxoacyl-L-alanyl-D-isoglutamines on their immunorestoration activity in vivo. Eur. J. Med. Chem. 31:1996;927-933
14. Barton D.H.R., Camara J., Dalko P., Gero S.D. Synthesis of biologically active carbocyclic analogues of N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP). J. Org. Chem. 54:1989;3764-3766
15. Gobec S., Urleb U., Simčič S., Wraber B. Synthesis and modulation of cytokine production by two new adamantane substituted acyclic desmuramyldipeptide analogs. Pharmazie. 56:2001;523-526
16. Dukor P., Dietrich F.M. Immunosupression by thalidomide? Lancet. 1:1967;569-570
17. Shannon E.J., Morales M.J., Sandoval F. Immunomodulatory assays to study structure-activity relationships of thalidomide. Immunopharmacology. 35:1997;203-212
18. Kaplan G., Moreira A.L. TNF alpha regulation of HIV-1: Biology and therapy. Res. Immunol. 145:1994;685-689
19. Hashimoto Y. Novel biological response modifiers derived from thalidomide. Curr. Med. Chem. 5:1998;163-178
20. Miyachi H., Azuma A., Ogasawara A., Uchimura E., Watanabe N., Kobayashi Y., Kato F., Kato M., Hashimoto Y. Novel biological response modifiers: Phthalimides with tumor necrosis factor-α production-regulating activity. J. Med. Chem. 40:1997;2858-2865
21. Jacobiec T., Glama I., Kowlaczyk-Bromisz S.H., Stankiewicz J., Zawisza T. Studies on the derivatives of 2-amino-4-p-chlorophenylthiazole-5-acetic acid. I. Synthesis and pharmacological analysis of acylderivatives of 2-amino-4-p-chlorophenylthiazole-5-acetic acid. Arch. Immunol. Ther. Exp. 27:1979;777-794
22. Bosies E., Heerdt R., Gall R., Bicker U., Ziegler A.E. Aziridine carboxylic acid derivatives, Ger. Offen. 2740, 248, 15 Mar 1977. Chem. Abstr. 90:1979;203849q
23. Urleb U., Krbavčič A., Sollner M., Kikelj D., Pečar S. Synthesis of phthalimido-desmuramylpeptide analogues as potential immunomodulating agents. Arch. Pharm. (Weinheim). 328:1995;113-117
24. Ochi C., Norisada N., Moriguchi M., Štalc A., Urleb U., Muraoka S. Interleukin-10 inducing activity of LK423, a phthalimido-desmuramyldipeptide compound. Arzneim.-Forsch./Drug Res. 49:1999;72-79
25. Moriguchi M., Urabe K., Norisada N., Ochi C., Štalc A., Urleb U., Muraoka S. Therapeutic effects of LK 423, a phthalimido-desmuramyldipeptide compound, on dextran sulphate sodium-induced colitis in rodents through restoring their interleukin-10 producing capacity. Arzneim.-Forsch./Drug Res. 49:1999;184-192
26. Simčič S., Wraber B., Sollner M., Urleb U., Gobec S. Modulation of tumor necrosis factor production with desmuramyldipeptide analogues. Pflug. Arch. Eur. J. Phy. 440:2000;R64-R66
27. Urleb U., Gobec S., Prelog D. Synthesis and activity of phosphono desmuramyldipeptide analogs. Lett. Pept. Sci. 2:1995;193-197
28. Gobec S., Urleb U. Synthesis of new phosphonamidate and phosphinamide desmuramyldipeptide analogs. Lett. Pept. Sci. 5:1998;109-114
29. Gobec S., Urleb U. Synthesis of phosphono phthalimido-desmuramyldipeptide analogs. Phosphorus, Sulfur, Silicon Relat. Elem. 156:2000;125-133
30. Gobec S., Urleb U. Synthesis of new lipophilic phosphonate and phosphonamidate analogues of N-acetylmuramyl-L-alanyl-D-isoglutamine related to LK 423. Molecules. 7:2002;394-404
31. Dzierzbicka K., Godowska M., Kolodziejczyk A.M. Influence of immunomodulators of the type MDP on secrecion and activity of cytokines. Postepy Biochem. 44:1998;216-219
32. Suzuki K., Torii K., Hida S., Hayashi H., Hiyama Y., Oomoto Y., Takii T., Chiba T., Onozaki K. Differences in interleukin-1 (IL-1), IL-6, tumor-necrosis-factor and IL-1 receptor antagonist production by human monocytes stimulated with muramyl dipeptide (MDP) and its stearoyl derivative, romurtide. Immunopharmacology. 28:1994;31-38
33. Bahr G.M., Darcissac E., Pouillart P.R., Chedid L.A. Synergistic effects between recombinant interleukin-2 and the synthetic immunomodulator murabutide: Selective enhancement of cytokine release and potentiation of antitumor activity. J. Interferon Cytokine Res. 16:1996;169-178
34. Worth L.L., Jia S.F., An T., Kleinerman E.S. ImmTher, a lipophilic disaccharide derivative of muramyl dipeptide, up-regulates specific monocyte cytokine genes and activates monocyte-mediated tumoricidal activity. Cancer Immunol. Immunother. 48:1999;312-320
35. Shiba T., Okada S., Kusumoto S., Azuma I., Yamamura Y. Synthesis of 6-O-mycolyl-N-acetyl-muramyl-L-alanyl-D-isoglutamine with antitumor activity. Bull. Chem. Soc. Jpn. 51:1978;3307-3311
36. Kusumoto S., Inage M., Shiba T., Azuma I., Yamamura Y. Synthesis of long chain fatty acid esters of N-acetyl-muramyl-L-alanyl-D-isoglutamine in relation to anti-tumor activity. Tetrahedron Lett. 49:1978;4895-4899
37. Kobayashi S., Fukuda T., Yukimasa H., Fujino M., Azuma I., Yamamura Y. Synthesis, and the adjuvant and tumor-suppressive activities of quinonyl muramyl dipeptides. Bull. Chem. Soc. Jpn. 57:1984;3182-3196
38. Dzierzbicka K., Kolodziejczyk A.M., Wysocka-Skrzela B., Myśliwski A., Sosnowska D. Synthesis and antitumor activity of conjugates of muramyldipeptide, normuramyldipeptide, and desmuramylpeptides with acridine/acridone derivatives. J. Med. Chem. 44:2001;3606-3615
39. Dzierzbicka K., Kolodziejczyk A.M. Synthesis and antitumor activity of conjugates of muramyldipeptide or normuramyldipeptide with hydroxyacridine/ acridone derivatives. J. Med. Chem. 46:2003;183-189
40. Dzierzbicka K., Trzonkowski P., Sewerynek P., Myśliwski A. Synthesis and cytotoxic activity of conjugates of muramyl and normuramyl dipeptides with batracylin derivatives. J. Med. Chem. 46:2003;978-986
41. Filipič M., Kuhar P., Žegura B., Urleb U., Gobec S. Determination of cytotoxic activity of adamantyl-desmuramyl dipeptides. Pharmazie. 58:2003;442-443
42. Hall I.H., Wong O.T., Chapmann J.M. Cytotoxicity of imides-N-alkyl semicarbazones, thiosemicarbazones, acetylhydrazones and related derivatives. Anti-Cancer Drugs. 6:1995;147-153
43. Hall I.H., Wong O.T., Scovill J.P. The cytotoxicity of N-pyridinyl and N-quinolinyl substituted derivatives of phthalimide and succinimide. Biomed. and Pharmacother. 5:1995;251-258
44. Martin S.L., McDowell A., Lynas J.F., Nelson J., Walker B. A study of the anti-invasive properties of N-alpha-phthalimidomethyl-ketomethylene tripeptide-based metalloprotease inhibitors. J. Pharm. Pharmacol. 53:2001;333-343
45. Lentzch S., Rogers M.S., Leblanc R., Birsner A.E., Shah J.H., Treston A.M., Anderson K.C., D'Amato R.J. S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res. 62:2002;2300-2305
46. Sanyal U., Dutta S., Das H. Evaluation of the anticancer property of a new α-methylene-γ-lactone derivative of phthalimide. Neoplasma. 42:1995;129-132
47. Nefkens G.H.L., Tesser G.I., Nivard R.J.F. A simple preparation of phthaloyl amino acids via a mild phthaloylation. Rec. Trav. Chim. Pays-Bas. 79:1960;688-698
48. Mosmann T. Rapid colorimetric assay for cellular growth and survival - application to proliferation and cyto-toxicity assays. J. Immunol. Meth. 65:1983;55-63
49. Kocjan T., Wraber B., Repnik U., Hojker S. Changes in Th1/Th2 cytokine balance in Graves' disease. Pflug. Arch. Eur. J. Phy. 440:2000;R94-R95
50. Watford W.T., Moriguchi M., Morinobu A., O'Shea J.J. The biology of IL-12: coordinating innate and adaptive immune responsens. Cytokine Growth Factor Rev. 14:2003;361-368
51. Abbas A.K., Lichtman A.H. Cytokines. Cellular and molecular immunology. 2003;243-274 W.B. Saunders Company, Philadelphia
52. Trinchieri G. Cytokines acting on or secreted by macrophages during intracellular infection (IL-10, IL-12, IFN-γ). Curr. Opin. Immunol. 9:1997;17-23
53. Oppenheim J.J., Feldmann M. Cytokine reference. 2001;Academic Press, San Diego